ONC Stock Summary and Trading Ideas (Beone Medicines Ltd. - American Depositary Shares | NASDAQ:ONC)

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.

Beone Medicines Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ONC.

As of December 26, 2025, ONC stock price climbed to $312.39 with 95,574 million shares trading.

ONC has a beta of 0.57, meaning it tends to be less sensitive to market movements. ONC has a correlation of 0.05 to the broad based SPY ETF.

ONC has a market cap of $34.57 billion. This is considered a Large Cap stock.

Last quarter Beone Medicines Ltd. - American Depositary Shares reported $1 billion in Revenue and $2.65 earnings per share. This beat revenue expectation by $58 million and exceeded earnings estimates by $1.85.

The top ETF exchange traded funds that ONC belongs to (by Net Assets): IBB, FBT, BBH, CGGE, CGIE.

ONC support price is $304.26 and resistance is $319.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONC shares will trade within this expected range on the day.